Overview
We are currently seeking a full-time Research Associate TCR Discovery* to support our team in the development and implementation of next generation T cell receptors (TCRs) for our innovative Adoptive Cell Therapy (ACT) products. You will work within the Immatics Discovery Unit based in Tuebingen (Germany) in the department of TCR Discovery, interacting with colleagues from other research departments in a highly interdisciplinary environment.
Your mission
Your main responsibilities will include but are not limited to the following tasks:
- Cell culture of tumor cell lines and primary T cells, functional T cell assays, flow cytometric measurements
- Molecular biology: PCR, sample preparation for next generation sequencing
- Production of lentiviral particles for the modification of primary human lymphocytes and cell lines
- Planning, implementation, evaluation and documentation of the corresponding experiments
- Establishment/ further development of new methods and processes in the laboratory including drafting of associated operating instructions (SOPs)
- Management of lab-associated overhead work, e.g., device management
Why us?
We are a committed and inspired team and cherish the collegial, highly motivated and family-friendly atmosphere within Immatics. Our culture allows for a high level of originality, independent thinking and initiative. We believe in supporting our employees’ professional and social skills: We enable them to join conferences and trainings as well as to enjoy our Immatics benefits – e.g. job bike, job ticket, Health Programs, childcare benefits, relocation allowance, Company summer and winter events.
Notice
*We value diversity and inclusion. Immatics N.V. and all Immatics subsidiaries are equal opportunity employers that evaluate qualified applicants without regard to race, color, national origin, religion, sex, age, marital status, disability, veteran status, sexual orientation, gender identity, or other characteristics protected by law.
About Us
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.